Wuhan Hiteck Biological Pharma Co Ltd (300683) — Capital Reinvestment Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Capital Reinvestment Ratio of 1.14x as of September 2024, meaning it reinvests 1% of its operating cash flow (CN¥4.86 Million) in capital expenditures (CN¥5.52 Million). See Wuhan Hiteck Biological Pharma Co Ltd (300683) net asset quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Capital Reinvestment Ratio (2013–2024)
This chart tracks Wuhan Hiteck Biological Pharma Co Ltd's Capital Reinvestment Ratio across 11 annual periods. Check Wuhan Hiteck Biological Pharma Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
Year-by-year Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. For live market cap and broader valuation context, see Wuhan Hiteck Biological Pharma Co Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.90x | CN¥22.69 Million | CN¥43.08 Million | ▼ -94.0% |
| 2023 | 31.51x | CN¥5.31 Million | CN¥167.44 Million | ▲ +860.5% |
| 2022 | 3.28x | CN¥53.03 Million | CN¥173.97 Million | ▼ -84.0% |
| 2021 | 20.44x | CN¥12.09 Million | CN¥247.11 Million | ▲ +1009.2% |
| 2019 | 1.84x | CN¥63.03 Million | CN¥116.15 Million | ▲ +249.9% |
| 2018 | 0.53x | CN¥73.42 Million | CN¥38.67 Million | ▲ +96.6% |
| 2017 | 0.27x | CN¥83.08 Million | CN¥22.25 Million | ▲ +74.8% |
| 2016 | 0.15x | CN¥143.86 Million | CN¥22.05 Million | ▲ +79.9% |
| 2015 | 0.09x | CN¥159.89 Million | CN¥13.62 Million | ▼ -26.3% |
| 2014 | 0.12x | CN¥135.40 Million | CN¥15.64 Million | ▼ -43.5% |
| 2013 | 0.20x | CN¥76.82 Million | CN¥15.71 Million | — |